Alpha Teknova (TKNO)
Makes catalog and custom reagents for therapy, vaccine, diagnostic, and research workflows.
$9.35
vs last close+0.58 (+6.61%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 8 | 9 | 10 | 10 | 9 | 10 | 10 | 10 | 10 | 11 | 12 |
| Cost of revenue | 7 | 7 | 7 | 7 | 9 | 7 | 7 | 6 | 7 | 7 | 8 | 7 |
| Gross profit | 1 | 1 | 2 | 3 | 0 | 2 | 3 | 4 | 3 | 3 | 3 | 5 |
| 10 | 12 | 10 | 8 | 8 | 8 | 8 | 7 | 7 | 8 | 8 | 8 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 9 | 8 | 9 | 7 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | 7 | |
| Selling & marketing | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| General & administrative | 6 | 6 | 7 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Other expenses | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −9 | −11 | −8 | −5 | −7 | −6 | −5 | −3 | −4 | −5 | −4 | −3 |
| −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 1 | −2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −10 | −11 | −8 | −5 | −8 | −6 | −5 | −4 | −4 | −5 | −5 | −3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −10 | −11 | −8 | −5 | −8 | −6 | −5 | −4 | −4 | −5 | −5 | −3 |
| Net income | −10 | −11 | −8 | −5 | −8 | −6 | −5 | −4 | −4 | −5 | −5 | −3 |
| EPS, basic | −$0.34 | −$0.26 | −$0.20 | −$0.13 | −$0.17 | −$0.11 | −$0.09 | −$0.07 | −$0.08 | −$0.09 | −$0.09 | −$0.06 |
| EPS, diluted | −$0.34 | −$0.26 | −$0.20 | −$0.13 | −$0.17 | −$0.11 | −$0.09 | −$0.07 | −$0.08 | −$0.09 | −$0.09 | −$0.06 |
| Weighted average shares, basic | 30 | 41 | 41 | 41 | 45 | 53 | 53 | 53 | 54 | 54 | 54 | 54 |
| Weighted average shares, diluted | 30 | 41 | 41 | 41 | 45 | 53 | 53 | 53 | 54 | 54 | 54 | 54 |
| EBITDA | −8 | −7 | −6 | −3 | −6 | −4 | −3 | −2 | −2 | −3 | −3 | −1 |
| Depreciation & amortization | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBIT | −9 | −9 | −8 | −5 | −7 | −6 | −4 | −3 | −4 | −5 | −4 | −3 |